loading
概要 ニュース 株価時系列 ディスカッション 予測 株式分割
前日終値:
$0.666
開ける：
$0.666
24時間の取引高:
91,392
Relative Volume:
0.54
時価総額：
$1.02M
収益：
$743.00K
当期純損益:
$-7.63M
株価収益率:
-0.2203
EPS:
-3
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
-35.51%
6か月 パフォーマンス:
-63.48%
1年 パフォーマンス:
-70.09%
1日の値動き範囲:
Value
$0.633
$0.67
1週間の範囲:
Value
$0.6301
$0.6799
52週間の値動き範囲:
Value
$0.6301
$3.12

Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile

Name
名前
Can-Fite Biopharma Ltd ADR
Name
セクター
Healthcare (1157)
Name
産業
Biotechnology (645)
Name
電話
972 3 924 1114
Name
住所
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Name
職員
7
Name
Twitter
@CanFitePharma
Name
次回の収益日
2024-12-31
Name
最新のSEC提出書
Name
CANF's Discussions on Twitter

CANF を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CANF
Can-Fite Biopharma Ltd ADR
 0.661 9.62M 743.00K -7.63M 0 -3.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
 454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
 660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
 313.67 37.96B 3.81B -644.79M -669.77M -6.24

Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2017-08-11 開始されました Maxim Group Buy
2016-10-19 再開されました ROTH Capital Buy
2016-08-29 再開されました Rodman & Renshaw Buy
2015-11-30 繰り返されました H.C. Wainwright Buy
2015-03-31 繰り返されました H.C. Wainwright Buy
2015-03-30 ダウングレード ROTH Capital Buy → Neutral
2014-12-29 繰り返されました ROTH Capital Buy
2014-11-18 開始されました H.C. Wainwright Buy
すべてを表示

Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース

pulisher
Aug 17, 2025

Full technical analysis of POST stockMarket Sentiment Summary & Breakout Confirmation Trade Signals - Newser

Aug 17, 2025
pulisher
Aug 05, 2025

What indicators show strength in Enterprise Products Partners L.P. Limited PartnershipIn-Depth Stock Trading Volume Analysis - Newser

Aug 05, 2025
pulisher
Jul 30, 2025

Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com

Jul 30, 2025
pulisher
Jul 28, 2025

Can-Fite BioPharma prices $5 million public offering of ADSs - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Can-Fite BioPharma prices $5 million public offering of ADSs By Investing.com - Investing.com India

Jul 28, 2025
pulisher
May 27, 2025

Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail

May 27, 2025
pulisher
Apr 25, 2025

Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com

Apr 25, 2025
pulisher
Apr 14, 2025

Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Can-Fite BioPharma announces $3M registered direct offering - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com

Apr 14, 2025
pulisher
Mar 03, 2025

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Dec 04, 2024

Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com

Dec 04, 2024
pulisher
Oct 18, 2024

Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com

Oct 18, 2024
pulisher
Aug 26, 2024

List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel

Aug 26, 2024
pulisher
Apr 03, 2024

Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com

Apr 03, 2024
pulisher
Nov 21, 2023

symbol__ Stock Quote Price and Forecast - CNN

Nov 21, 2023
pulisher
Jul 12, 2023

Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK

Jul 12, 2023
pulisher
Nov 04, 2022

Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo Finance

Nov 04, 2022
pulisher
Oct 19, 2022

Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici

Oct 19, 2022
pulisher
May 27, 2022

bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com

May 27, 2022
pulisher
Oct 14, 2020

4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks

Oct 14, 2020
pulisher
Jul 15, 2020

New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire

Jul 15, 2020
pulisher
Aug 24, 2019

10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance

Aug 24, 2019
pulisher
Aug 02, 2016

Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha

Aug 02, 2016
pulisher
Mar 20, 2014

Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire

Mar 20, 2014

Can-Fite Biopharma Ltd ADR (CANF) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

CANFに似た銘柄

biotechnology GMAB
$24.65
price up icon 0.94%
biotechnology INCY
$85.04
price down icon 1.72%
biotechnology SMMT
$26.20
price up icon 0.73%
biotechnology BNTX
$110.88
price up icon 0.10%
biotechnology INSM
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く
大文字化:     |  ボリューム (24 時間):